DAOVARD

This brand name is authorized in Nigeria.

Active ingredients

The drug DAOVARD contains one active pharmaceutical ingredient (API):

1	Glibenclamide UNII SX6K58TVWC - GLYBURIDE
	Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.
	Read more about Glibenclamide

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-5944	Tablet	Daovard Tablet TAB 5 mg 6 x 10's (in Alu/PVC blisters)	Uncoated tablet. White elongated flat uncoated tablets with ‘DAOVARD’ embossed on one side & breakline on other side of each tablet. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses	03/08/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BB01	Glibenclamide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives
Discover more medicines within A10BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-5944